1. Home
  2. JAGX vs PRFX Comparison

JAGX vs PRFX Comparison

Compare JAGX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$2.73

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$1.51

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JAGX
PRFX
Founded
2013
2007
Country
United States
Israel
Employees
47
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.6M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
JAGX
PRFX
Price
$2.73
$1.51
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$60.00
N/A
AVG Volume (30 Days)
71.5K
1.8M
Earning Date
04-07-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
82.42
N/A
EPS
N/A
N/A
Revenue
$11,511,000.00
N/A
Revenue This Year
$61.58
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.58
52 Week High
$8.00
$5.39

Technical Indicators

Market Signals
Indicator
JAGX
PRFX
Relative Strength Index (RSI) 47.96 43.87
Support Level $1.74 $0.95
Resistance Level $4.13 $1.54
Average True Range (ATR) 0.39 0.40
MACD -0.16 0.04
Stochastic Oscillator 2.11 5.72

Price Performance

Historical Comparison
JAGX
PRFX

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

About PRFX PainReform Ltd.

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.

Share on Social Networks: